Rovina Ruslami is the head of Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. She completed a residency in the Internal Medicine at the same institution in 2001, and obtained her PhD in Clinical Pharmacology of anti tuberculosis treatment at the Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands in 2009. She completed postdoctoral fellowship form KNAW, the Netherlands, and continue working on the area of optimizing the treatment of TB Meningitis. Her current research activity is as the PI of ReDEFINe study - (Rifampicin Dose Finding Study), a double blind randomized control trial phase IIb Clinical Trial, funded by USAID & NIH through PEER Health program (NCT02169882).
Besides working on TB Meningitis, she is also interested at the concurrent TB and Diabetes Mellitus, focusing on improving care for both TB and Diabetes Mellitus. She is the site co-PI of TANDEM project (www.tandem-fp7.eu) funded by the EU.